Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (286)	5/15/2014 7:34:36 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 321

>> Tough small cap sledding << My other small cap abstract-release play (tgtx) recovered today for a solid 10% plus from where I entered. I'm already out, so...... thank you, Andy Biotech, for the timely and generous pointer! But I don't know what to say re. arry. IMO, the LEE011/MEK162 abstract was THE intriguing lead. Sigh. Six months of extra results to be discussed at the meeting, maybe that will add some spark. Anybody note that, regarding AZN, the new Board member (Chuck Baum) played a big role in oncology at Pfizer? Know him from SyStemix (a postdoc with Irv W., he spent most of his time at the company). Super nice guy, real bright.... should be the correct individual to advise the company re. selumetinib. And more. Best of luck, all!